SCHEMBL7330774

SCHEMBL7330774

CNc1cc(C)ccc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.54
ALOX15 P16050 2/20 0.54
CYP3A4 P08684 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TP53 P04637 1/20 0.54
THRB P10828 1/20 0.54
ALDH1A1 P00352 4/20 0.46
NPC1 O15118 3/20 0.44
MAPT P10636 3/20 0.44
RAB9A P51151 2/20 0.44
MAPK1 P28482 2/20 0.44
PKM P14618 1/20 0.44
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HSD17B10 Q99714 1/20 0.43
CA1 P00915 1/20 0.41
GAA P10253 2/20 0.41
TSHR P16473 1/20 0.41
PRKCI P41743 1/20 0.38
HTT P42858 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7262816 0.81 TDP1 (0.54) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL10140559 0.81 TDP1 (0.54) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL14610894 0.79 TDP1 (0.52) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL5605835 0.78 CYP3A4 (0.48) TDP1ALOX15CYP3A4ALDH1A1MAPT
SCHEMBL16543023 0.78 CASP1 (0.42) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL8338686 0.77 TDP1 (0.50) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL12889181 0.77 HPGD (0.45) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL6707715 0.76 TDP1 (0.48) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL2014730 0.76 LMNA (0.50) TDP1ALOX15CYP3A4SMN1; SMN2TP53
SCHEMBL22592437 0.76 PRKCI (0.40) TDP1ALOX15CYP3A4SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802136-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-10-31 US disclosed
WO-2023191536-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF 고려대학교 산학협력단 2023-10-05 WO disclosed
EP-4249525-A1 METHOD FOR MANUFACTURING PERFLUOROELASTOMER AQUEOUS DISPERSION, COMPOSITION, CROSSLINKABLE COMPOSITION, AND CROSSLINKED PRODUCT DAIKIN INDUSTRIES, LTD. (JP) 2023-09-27 EP disclosed
EP-3573960-B1 N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES GENFIT (FR) 2023-08-16 EP disclosed
EP-4198020-A1 ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME, AND ELECTRONIC APPARATUS Shaanxi Lighte Optoelectronics Material Co., Ltd. (CN) 2023-06-21 EP disclosed
WO-2023005614-A1 FRAME STRUCTURE-BASED NANOPARTICLE USED FOR MASS CYTOMETRY AND PREPARATION METHOD THEREFOR 浙江大学 2023-02-02 WO disclosed
EP-3715423-B1 HIGH WET FAST DISPERSE DYE MIXTURES OF N-[4-(5-FLUORO-2,4-DINITRO-PHENYLAZO)-PHENYL]-AMINE DERIVATIVES AND N-[4-(4-NITRO-PHENYLAZO)-PHENYL]-AMINE DERIVATIVES DYSTAR COLOURS DISTRIB GMBH (DE) 2022-05-11 EP disclosed
WO-2021139775-A1 PYRIDONE COMPOUND AND APPLICATION 江苏先声药业有限公司 2021-07-15 WO disclosed
EP-3162802-B1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME NIHON MEDIPHYSICS CO LTD (JP) 2020-08-19 EP disclosed
US-20200140471-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2020-05-07 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
EP-1711184-B1 (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA NV (BE) 2007-07-18 EP disclosed
WO-2004083174-A2 SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed
CN-1027536-C Process for producing 4,5,6,7-tetrahydrobenzimidazole derivatives YAMANOUCHI PHARMA CO LTD (JP) 1995-02-01 CN disclosed
EP-0376624-B1 4,5,6,7-Tetrahydrobenzimidazole derivatives and their preparation YAMANOUCHI PHARMA CO LTD (JP) 1994-09-14 EP disclosed
US-4977175-A GASTROINTESTINAL DISORDERS, ANTIEMETICS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1990-12-11 US disclosed
CN-1043706-A 4,5,6,7-tetrahydrobenzene benzimidazole derivative preparation method YAMANOUCHI PHARMA CO LTD (JP) 1990-07-11 CN disclosed
EP-0376624-A1 4,5,6,7-Tetrahydrobenzimidazole derivatives and their preparation YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1990-07-04 EP disclosed
US-4173631-A ANTIPROTOZOA AGENTS, PARASITICIDES MERCK & CO., INC. (US) 1979-11-06 US disclosed
US-3931215-A OPTICAL BRIGHTENERS HOECHST AKTIENGESELLSCHAFT (DT) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140471-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OSBP, OCIAD1, OCIAD2 TDP1 1645/4885ALOX15 97/4885CYP3A4 264/4885
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 TDP1 4163/4885ALOX15 3144/4885CYP3A4 1310/4885
US-11802136-B2 Organic electroluminescent materials and devices OSBP, OCIAD1, OCIAD2 TDP1 1645/4885ALOX15 97/4885CYP3A4 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.